Literature DB >> 8237378

[Pharmacokinetics of dihydroqinghaosu in human volunteers and comparison with qinghaosu].

K C Zhao1, Z Y Song.   

Abstract

Qinghaosu (QHS), also known as artemisinin and arteannuin, is a novel type of sesquiterpene with a peroxide linkage isolated from the Chinese herb Artemisia annua L. Since its discovery as an antimalarial with low toxicity, hundreds of derivatives have been synthesized among them artesunate (ATS), artemether (ATM) and dihydroqinghaosu (DHQHS) were found to be more active than QHS itself. A suppository of QHS, a dual-pack dosage form of ATS (artesunic acid to be dissolved in sodium bicarbonate solution just before iv injection) and an oil solution of ATM for im injection had been approved by our Ministry of Health for clinical use. However, a preparation for oral administration is still not available. We have reported that when dogs were given QHS tablets orally at the dose of 70 mg/kg, no drug was detected in the serum using the RIA method, whereas appreciable serum concentration was found by the same method when dogs were given DHQHS tablets at a dose as low as 10 mg/kg. This paper reports the pharmacokinetics of DHQHS in man studied with the RIA method and compared with QHS. When DHQHS in tablet form was given to human volunteers at doses of 1.1-2.2 mg/kg, peak serum levels of 0.13-0.71 micrograms/ml were obtained in 1.33 h with MRT of 2.26-2.36 h. When QHS tablets were given at the dose as high as 15 mg/kg, however, the peak serum level found in 1.5 h was only 0.09 microgram/ml with MRT of 1.33 h. Therefore, the bioavailability of QHS tablets is only 1.62-10.08% that of DHQHS.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8237378

Source DB:  PubMed          Journal:  Yao Xue Xue Bao        ISSN: 0513-4870


  10 in total

1.  Establishment of an in vitro screening model for neurodegeneration induced by antimalarial drugs of the artemisinin-type..

Authors:  G Schmuck; R K Haynes
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 2.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  In-vivo activity of dihydroartemisinin against Schistosoma japonicum.

Authors:  H-J Li; W Wang; G-L Qu; Y-H Tao; Y-T Xing; Y-Z Li; J-Y Wei; J-R Dai; Y-S Liang
Journal:  Ann Trop Med Parasitol       Date:  2011-03

4.  The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria.

Authors:  Kenneth F Ilett; Kevin T Batty; Shane M Powell; Tran Quang Binh; Le Thi Anh Thu; Hoang Lan Phuong; Nguyen Canh Hung; Timothy M E Davis
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

Review 5.  Pharmacokinetics of artemisinin-type compounds.

Authors:  V Navaratnam; S M Mansor; N W Sit; J Grace; Q Li; P Olliaro
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

6.  Declining concentrations of dihydroartemisinin in plasma during 5-day oral treatment with artesunate for Falciparum malaria.

Authors:  N X Khanh; P J de Vries; L D Ha; C J van Boxtel; R Koopmans; P A Kager
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

7.  Dried-leaf Artemisia annua: A practical malaria therapeutic for developing countries?

Authors:  Pamela J Weathers; Melissa Towler; Ahmed Hassanali; Pierre Lutgen; Patrick Ogwang Engeu
Journal:  World J Pharmacol       Date:  2014-12-09

Review 8.  Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria.

Authors:  P J de Vries; T K Dien
Journal:  Drugs       Date:  1996-12       Impact factor: 9.546

9.  Neurotoxicity of artemisinin analogs in vitro.

Authors:  D L Wesche; M A DeCoster; F C Tortella; T G Brewer
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

10.  New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics.

Authors:  Si-Yuan Pan; Shu-Feng Zhou; Si-Hua Gao; Zhi-Ling Yu; Shuo-Feng Zhang; Min-Ke Tang; Jian-Ning Sun; Dik-Lung Ma; Yi-Fan Han; Wang-Fun Fong; Kam-Ming Ko
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-24       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.